Computational pathology-informed immune biomarker for trastuzumab benefit in HER2+ breast cancer: Validation in NSABP B-41 clinical trial. Analysis of event-free survival (EFS) of stromal tumor ...
On the basis of these facts, we strongly believe that the position of hormonal drugs for preselected groups of patients with EC should be redefined in the context of the molecular classification. To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results